MustGrow Biologics Achieves Breakthrough in Potato Yield with TerraSanteTM

The latest announcement is out from MustGrow Biologics ( (TSE:MGRO) ).

MustGrow Biologics has reported significant success with its TerraSanteTM biofertility product in large-scale potato field trials in Washington State and Idaho. The trials demonstrated a notable increase in potato yield, size, and quality, resulting in an estimated US$5,000 increase in value per acre at a cost of only US$180 per acre for TerraSanteTM. The product also showed substantial benefits to soil health when used alongside existing grower programs, aligning with MustGrow’s focus on improving soil and ecological health through its mustard-derived technologies.

Spark’s Take on TSE:MGRO Stock

According to Spark, TipRanks’ AI Analyst, TSE:MGRO is a Neutral.

MustGrow Biologics’ overall stock score of 57 reflects significant revenue growth and strategic market expansions, countered by ongoing financial challenges and valuation concerns. The company’s strong gross margins and low leverage are positives, but the persistent net losses and negative cash flow remain crucial risks.

To see Spark’s full report on TSE:MGRO stock, click here.

More about MustGrow Biologics

MustGrow Biologics Corp. is a fully integrated provider of innovative biological and regenerative agriculture solutions, focusing on sustainable farming. The company offers eco-friendly alternatives to synthetic chemicals and fertilizers, with a portfolio that includes micronutrients, nitrogen stabilizers, biostimulants, adjuvants, and foliar products. MustGrow’s proprietary products are derived from mustard and developed into organic biocontrol and biofertility solutions, aiming to replace banned or restricted synthetic chemicals.

Average Trading Volume: 22,274

Technical Sentiment Signal: Sell

Current Market Cap: C$33.55M

For an in-depth examination of MGRO stock, go to TipRanks’ Overview page.